This article is sponsored by Otsuka America Pharmaceutical, Inc. In long-term care environments, it’s not uncommon for site staff including nurses, administrators, physical therapists, physicians and ...
PHILADELPHIA, Pennsylvania — A combination of dextromethorphan and quinidine (Nuedexta, Avanir Pharmaceuticals) significantly reduced symptoms of pseudobulbar affect (PBA) among patients with dementia ...
For five years, Rebecca (not her real name) often erupted in frequent crying spells. But thanks to her medical team’s vigilance and a good dose of serendipity, she’s now tear-free. Rebecca was 54 ...
Perhaps this situation sounds familiar to you: you are having a calm discussion with a friend about a topic you don't find emotional whatsoever, and you notice that tears are welling up in your friend ...
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and ...
March is Multiple Sclerosis Awareness Month, a time to shine a light on ms, a disease that affects an estimated 900,000 people in the U.S. Today, we explore a less talked about and often misdiagnosed ...
Based on positive phase III study results, Metis Techbio is planning to file an NDA for its AI-derived orally disintegrating tablet drug candidate for pseudobulbar affect, MTS-004, in China next year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results